New data presented at breast cancer symposium

4th December 2017

Agendia has announced the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS), highlighting the value of its MammaPrint 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint Breast Cancer Molecular Subtyping Test. A total of 11 posters and discussions are being presented at SABCS, which will take place at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 5-9, 2017.

The posters and presentations feature important new data from the I-SPY 2 trial (Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer) and the IMPACt trial (Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry) as well as cost-effectiveness data and performance data across patient populations of different ages, and those affected by obesity and other metabolic factors.

A highlight will be the oral presentation on Thursday, December 7 which will show the first long-term survival results from the I-SPY 2 trial for patients pre-selected by MammaPrint.

Dr. William Audeh, Chief Medical Officer at Agendia, said: “The breadth and depth of the new data being presented at SABCS clearly demonstrates the broad application of MammaPrint and BluePrint in helping to guide breast cancer treatment decisions in a wide range of patient populations. In addition, it underscores the important role that MammaPrint can take in clinical trials like I-SPY 2. Physicians and their patients want to feel confident that they are using the test that is backed with the highest level of clinical evidence and the most comprehensive data, and MammaPrint can provide this reassurance.”





To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited